Form 4: VolitionRX Director Alan Colman Receives Stock Award in Lieu of Cash Compensation

Director Alan Colman received 14,840 restricted stock units (RSUs) in VolitionRX Ltd in lieu of cash compensation on March 1, 2025.

Summary

• Alan Colman, a director of VolitionRX Ltd, received 14,840 restricted stock units (RSUs) on March 1, 2025.
• The RSUs were awarded under the Issuer's 2024 Stock Incentive Plan as a substitute for cash compensation.
• The RSUs vest in three installments of 4,947 units, 4,947 units, and 4,946 units on March 1, 2025, April 1, 2025 and May 1, 2025, respectively.
• The RSUs are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date.
• Upon vesting and settlement, Colman will receive shares of common stock equal to the number of RSUs that have vested.
• Following the transaction, Colman directly owns 245,364 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of RSUs is a standard practice and suggests confidence in the company's future performance. The use of RSUs instead of cash is a positive sign for the company's financial management.

Positives

• The award of RSUs to a director aligns their interests with those of the shareholders.
• Using RSUs instead of cash may preserve the company's cash reserves.

Industry Context

Stock awards to directors are a common practice in publicly traded companies to align management's interests with those of shareholders and to conserve cash.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, aligning director interests with company performance.
• Employees may see the RSU grant as a sign of the company's commitment to its leadership.

Key Dates